Partial
Mostly Aligned
Patient Risk:
Low
Summary
Partial alignment. The AI response correctly reflects on-label elements such as the restricted indication to a premenopausal, specific HSDD population and the presence of alcohol/medication interaction warnings, but it includes EU-specific claims not present in the FDA-approved label and omits other on-label details.
Category Scores
Accurate Statements
The use is limited to that specific patient group.
Indication limited to premenopausal women <65 with acquired generalized HSDD not due to coexisting conditions, relationship problems, or medication effects.
Flibanserin should not be used for postmenopausal HSDD or other sexual dysfunction types.
Indication specifies women <65; not indicated for men; not indicated to enhance sexual performance (inferred from Limitations of Use).
Flibanserin has clinically important restrictions around alcohol use and certain medicines that can increase the risk of serious side effects.
5.1, 5.2, 5.3, and 7 sections cover alcohol interactions and drug interactions.
Unsupported Statements
Flibanserin (Addyi) is approved for use in the European Union.
EU approval status is not described in the FDA-approved label provided.
In the EU, the product is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) who have had distress as a result of their condition.
EU-specific indication is not described in the FDA-approved label provided.
There are no changes to the underlying EU approval status for flibanserin indicated in the available sources used here.
EU approval status changes are not addressed in the FDA-approved label provided.
EU prescribing is tied to the labeled indication—premenopausal women with acquired, generalized HSDD and distress.
EU-specific prescribing guidance is not described in the FDA-approved label provided.
Clinicians generally need to confirm those criteria before prescribing.
While the label describes the on-label population, the claim about EU practice is not described in the FDA-approved label provided.
The precautions contribute to flibanserin prescribing being tightly controlled in practice across many markets, including the EU.
EU practice details are not described in the FDA-approved label provided.
Contradictions
Important Omissions
No explicit on-label dosing details (e.g., 100 mg once daily at bedtime) or administration instructions are mentioned in the evaluated claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims acknowledge alcohol-related and drug interaction risks that are described in the label; no additional risk information is introduced.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
EU-specific claims not present in FDA label; missing explicit dosing/administration details; some claims rely on non-label EU context.
Suggested Improvement
Restrict statements to FDA-labeled indications and warnings; provide exact dosing and administration details; avoid EU-specific claims unless clearly labeled as such and sourced from appropriate regulatory documents.